Once-daily tigecycline for outpatient parenteral antibiotic therapy: a single-centre observational study.

ABSTRACT:

Background

Tigecycline has potential utility in the treatment of complex polymicrobial infections or those caused by MDR organisms in the ambulatory care setting owing to its breadth of antimicrobial coverage. Whilst licensed for twice-daily IV administration, its long half-life permits once-daily administration, which may facilitate successful outpatient parenteral antibiotic therapy (OPAT).

Methods

A retrospective case series of patients receiving once-daily tigecycline under OPAT was analysed at a single-centre NHS acute hospital (January 2016-June 2018). Patient demographics, including comorbidities, antimicrobial indication, concurrent antimicrobial therapies, treatment duration and adverse events related to treatment were recorded using medical records. Treatment outco

SUBMITTER: Hughes S 

PROVIDER: S-EPMC8210309 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature